Proteus Digital Health, Inc

proteus.com

Welcome to Proteus Digital Health, a leading innovator spearheading the Digital Medicines revolution. Join our unique collection of innovative engineers, scientists, designers, developers, clinicians, and other digital health pioneers, and assist us with achieving our compelling vision, “Healthcare for Everyone, Everywhere.” Proteus is creating a new category of pharmaceuticals: Digital Medicines. Digital Medicine includes drugs that communicate when they’ve been taken, wearable sensors that capture physiologic response, applications that support patient self-care and physician decision making, and data analytics to serve the needs of doctors and health systems. The goal of Digital Medicine is to empower patients and their families, enable physicians and health systems to more effectively manage risk and ensure that outcomes are reliably achieved.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

WORKFORCE DRUG TESTING POSITIVITY CLIMBED TO HIGHEST RATE IN 16 YEARS, NEW QUEST DIAGNOSTICS DRUG TESTING INDEX™ ANALYSIS FINDS

Prnewswire | August 25, 2020

news image

The rate of workforce drug positivity hit a sixteen-year high in 2019, according to a new analysis released today by Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services. Positivity rates in the combined U.S. workforce increased in urine drug tests, climbing to the highest level since 2003 (4.5%) and more than 28% percent higher than the thirty-year low of 3.5 percent recorded between 2010 and 2012. In addition to overall increases in workforce drug ...

Read More

GLOBAL OXYMETAZOLINE MARKET 2020 – COMPLEX PHARMACEUTICAL, ALLERGAN, ALTAIRE PHARMACEUTICALS, HEALTH LIFE OF USA

bccourier | April 16, 2020

news image

Global Oxymetazoline Market research report delivers the analysis of the market outlook, framework, and socio-economic impacts. This report tries to covers the authenticate information of the market size, share, product footprint, revenue, and progress rate. All this information driven by primary and secondary researches, with reliable and authentic projections regarding the technical jargon. This study assesses the current landscape of the ever-evolving business sector and the present and futur...

Read More

Business Insights

EX-BIOCON TEAM SYMBIO GENERRICS COMPLETES CAPITAL RAISE FROM ASCENT CAPITAL

Symbio Generrics | November 25, 2022

news image

Symbio Generrics India Private Limited a specialized Active Pharmaceutical Ingredients & Intermediates manufacturing and marketing organization, announced that it has completed an equity capital raise from Ascent Capital, a leading growth-capital focused private equity fund. Symbio was founded by pharmaceutical professionals, Salim Shaikh and Abhijit Kale. They were soon joined by the third promoter, Akash Puranik; all of whom possess decades of experience in the global pharma...

Read More

Pharma Tech

EMERALD HEALTH PHARMACEUTICALS REPORTS DATA SHOWING NOVEL DRUG CANDIDATE IS FIRST-IN-CLASS B55Α/PP2A ACTIVATOR

Emerald Health Pharmaceuticals | October 14, 2022

news image

Emerald Health Pharmaceuticals Inc. a clinical-stage biopharmaceutical company developing a new class of medicines to treat neurodegenerative, autoimmune and other diseases, today announced the publication of a scientific article in the peer-reviewed Journal of Neuroinflammation highlighting additional data supporting the unique mechanism of action of EHP-101, the company’s first-in-class drug candidate for the treatment of systemic sclerosis and multiple sclerosis. Titled &...

Read More
news image

WORKFORCE DRUG TESTING POSITIVITY CLIMBED TO HIGHEST RATE IN 16 YEARS, NEW QUEST DIAGNOSTICS DRUG TESTING INDEX™ ANALYSIS FINDS

Prnewswire | August 25, 2020

The rate of workforce drug positivity hit a sixteen-year high in 2019, according to a new analysis released today by Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services. Positivity rates in the combined U.S. workforce increased in urine drug tests, climbing to the highest level since 2003 (4.5%) and more than 28% percent higher than the thirty-year low of 3.5 percent recorded between 2010 and 2012. In addition to overall increases in workforce drug ...

Read More
news image

GLOBAL OXYMETAZOLINE MARKET 2020 – COMPLEX PHARMACEUTICAL, ALLERGAN, ALTAIRE PHARMACEUTICALS, HEALTH LIFE OF USA

bccourier | April 16, 2020

Global Oxymetazoline Market research report delivers the analysis of the market outlook, framework, and socio-economic impacts. This report tries to covers the authenticate information of the market size, share, product footprint, revenue, and progress rate. All this information driven by primary and secondary researches, with reliable and authentic projections regarding the technical jargon. This study assesses the current landscape of the ever-evolving business sector and the present and futur...

Read More
news image

Business Insights

EX-BIOCON TEAM SYMBIO GENERRICS COMPLETES CAPITAL RAISE FROM ASCENT CAPITAL

Symbio Generrics | November 25, 2022

Symbio Generrics India Private Limited a specialized Active Pharmaceutical Ingredients & Intermediates manufacturing and marketing organization, announced that it has completed an equity capital raise from Ascent Capital, a leading growth-capital focused private equity fund. Symbio was founded by pharmaceutical professionals, Salim Shaikh and Abhijit Kale. They were soon joined by the third promoter, Akash Puranik; all of whom possess decades of experience in the global pharma...

Read More
news image

Pharma Tech

EMERALD HEALTH PHARMACEUTICALS REPORTS DATA SHOWING NOVEL DRUG CANDIDATE IS FIRST-IN-CLASS B55Α/PP2A ACTIVATOR

Emerald Health Pharmaceuticals | October 14, 2022

Emerald Health Pharmaceuticals Inc. a clinical-stage biopharmaceutical company developing a new class of medicines to treat neurodegenerative, autoimmune and other diseases, today announced the publication of a scientific article in the peer-reviewed Journal of Neuroinflammation highlighting additional data supporting the unique mechanism of action of EHP-101, the company’s first-in-class drug candidate for the treatment of systemic sclerosis and multiple sclerosis. Titled &...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us